A Chemokine CXCL14 and Its Relationship to Biomarkers for Both Small and Non-Small Cell Carcinomas
DOI:
https://doi.org/10.52783/jns.v14.3318Keywords:
small cell carcinoma (SCLC), lung cancer(LC), CXCL14, non-small cell carcinoma (NSCLC)Abstract
Worldwide, lung cancer is still the biggest killer when it comes to cancer, arising from uncontrolled cell division in lung
tissues. A homeostatic chemokine with a high degree of conservation, CXCL14 is expressed in epidermal epithelia, playing
a key role in immune cell maturation and epithelial regulation. It is the only chemokine known to localize within the tumor
microenvironment, contributing to immune surveillance. This study aims to evaluate CXCL14 as a possible of biomarker a
prediction of lung cancer outcomes. The materials and methods are a case-control study conducted on 180 participants (aged
45–77): There were 36 cases of “SCLC is a kind of LC”, 54 cases of “LC of (NSCLC)”, and 90 were healthy controls.
CXCL14 levels were measured using ELISA, along with CBC, cholesterol, triglycerides, and liver enzymes (ALT, AST,
ALP). Statistical analysis assessed correlations between CXCL14 and (LC) progression. The findings for a study
demonstrated that CXCL-14 levels are seen to a significantly lower in stage III compared to stage IV in both NSCLC and
SCLC, with a more pronounced decline in NSCLC at stage IV. Linear regression showed a positive correlation between
CXCL14 and cholesterol, triglycerides, NLR, ALT, AST, and ALP, while a negative correlation was observed with
hemoglobin (Hb) and HDL. CXCL14 demonstrated high diagnostic accuracy, with cut-off values of 120.007 pg/mL for
SCLC (AUC = 0.846, p = 0.000) and 87.054 pg/mL for NSCLC (AUC is 0.832, p is 0.000). Conclusions, these findings
offer that CXCL14 is a promising biomarker for lung cancer diagnosis and monitoring. Its involvement in lung cancer cell
motility also highlights its potential role in predicting metastasis, making it a valuable tool for early detection and prognosis.
Downloads
Metrics
References
Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncol
Onkol. 2021;25(1):45-52.
Lorenzo-Gonzalez M, Torres-Duran M, Barbosa-Lorenzo R, Provencio-Pulla M, Barros-Dios JM, Ruano
Ravina A. Radon exposure: a major cause of lung cancer. Expert Rev Respir Med. 2019;13(9):839-850.
Xue Y, Wang L, Zhang Y, Zhao Y, Liu Y. Air pollution: A culprit of lung cancer. J Hazard Mater.
;434:128937. doi:https://doi.org/10.1016/j.jhazmat.2022.128937
Registry C, Report A. Iraqi Cancer Board CANCER REGISTRY OF IRAQ. Published online 2022.
Rodak O, Peris-D’iaz MD, Olbromski M, Podhorska-Okołów M, Dzikegiel P. Current landscape of non-small
cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy. Cancers
(Basel). 2021;13(18):4705.
Crosby D, Bhatia S, Brindle KM, et al. Early detection of cancer. Science (80- ). 2022;375(6586):eaay9040.
Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Int J Mol Sci. 2021;22(16).
doi:10.3390/ijms22168661
Latimer KM, Mott TF. Lung cancer: Diagnosis, treatment principles, and screening. Am Fam Physician.
;91(4):250-256.
Riley LK, Rupert J. Evaluation of patients with leukocytosis. Am Fam Physician. 2015;92(11):1004-1011.
Shiels MS, Shu XO, Chaturvedi AK, et al. A prospective study of immune and inflammation markers and risk
of lung cancer among female never smokers in Shanghai. Carcinogenesis. 2017;38(10):1004-1010.
Tsai YT, Schlom J, Donahue RN. Blood-based biomarkers in patients with non-small cell lung cancer treated
with immune checkpoint blockade. J Exp & Clin Cancer Res. 2024;43(1):82.
Shabgah AG, Al-Qaim ZH, Markov A, et al. Chemokine CXCL14; a double-edged sword in cancer
development. Int Immunopharmacol. 2021;97:107681.
Journal of Neonatal Surgery | Year: 2025 | Volume: 14 | Issue: 13s
pg. 520
Wisam Abdulameer Noman1, Hanaa Addai Ali
Chang TM, Chiang YC, Lee CW, et al. CXCL14 promotes metastasis of non-small cell lung cancer through
ACKR2-depended signaling pathway. Int J Biol Sci. 2023;19(5):1455.
Mayengbam SS, Singh A, Pillai AD, Bhat MK. Influence of cholesterol on cancer progression and therapy.
Transl Oncol. 2021;14(6):101043.
Chen W, Wang W, Zhou L, et al. Elevated AST/ALT ratio is associated with all-cause mortality and cancer
incident. J Clin Lab Anal. 2022;36(5):e24356.
Wang Y, Wang S, Niu Y, Ma B, Li J. Data mining suggests that CXCL14 gene silencing in colon cancer is due
to promoter methylation. Int J Mol Sci. 2023;24(22):16027.
Roelands J, Kuppen PJK, Ahmed EI, et al. An integrated tumor, immune and microbiome atlas of colon cancer.
Nat Med. 2023;29(5):1273-1286.
Zhou L, Zhang Y, Wei M, Du K, Lin J, Wei L. Comprehensive analysis of CXCL14 uncovers its role during
liver metastasis in colon cancer. BMC Gastroenterol. 2023;23(1):273.
Liu J, Wang D, Zhang C, et al. Identification of liver metastasis-associated genes in human colon carcinoma by
mRNA profiling. Chinese J Cancer Res. 2018;30(6):633.
Tian PF, Ma YC, Yue DS, et al. Plasma CXCL14 as a Candidate Biomarker for the Diagnosis of Lung Cancer.
Front Oncol. 2022;12:833866.
Kuzu OF, Noory MA, Robertson GP. The role of cholesterol in cancer. Cancer Res. 2016;76(8):2063-2070.
Drabkin HA, Gemmill RM. Cholesterol and the development of clear-cell renal carcinoma. Curr Opin
Pharmacol. 2012;12(6):742-750.
Llaverias G, Danilo C, Mercier I, et al. Role of cholesterol in the development and progression of breast cancer.
Am J Pathol. 2011;178(1):402-412.
dos Santos C, Fonseca I, Dias S, de Almeida JC. Plasma level of LDL-cholesterol at diagnosis is a predictor
factor of breast tumor progression. BMC Cancer. 2014;14:1-10.
Loosen SH, Kostev K, Luedde M, Luedde T, Roderburg C. Low blood levels of high-density lipoprotein (HDL)
cholesterol are positively associated with cancer. J Cancer Res Clin Oncol. 2022;148(11):3039-3046.
Kucharska-Newton AM, Rosamond WD, Schroeder JC, McNeill AM, Coresh J, Folsom AR. HDL-cholesterol
and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study. Lung cancer.
;61(3):292-300.
Li R, Zhu WJ, Wang F, Tang X, Luo F. AST/ALT ratio as a predictor of mortality and exacerbations of PM/DM
ILD in 1 year—a retrospective cohort study with 522 cases. Arthritis Res & Ther. 2020;22:1-9.
Sansa A, Venegas M del P, Valero C, et al. The aspartate aminotransaminase/alanine aminotransaminase (De
Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients. Head & Neck.
;43(7):2091-2100.
Almehmadi M, Salih M, Elmissbah TE, et al. Prevalence of anemia among Saudi patients with solid cancers at
diagnosis in King Faisal Hospital, Taif Province, Kingdom of Saudi Arabia. PLoS One. 2021;16(1):e0246202.
Zhou J, Liu H, Jiang S, Wang W. Role of tumor-associated neutrophils in lung cancer. Oncol Lett. 2022;25(1):2.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
